November 20, 2022 — Fed up. That’s where we are with stories about how people taking semaglutide for obesity are keeping people with diabetes from getting an adequate supply of the drug they need. Fed up, because it’s a stealthy way of expressing implicit bias against people living with obesity. The subtext is that those people don’t really need […]
November 16, 2022 — It’s a fact. Media needs your attention. Thus, journalistic standards live in in tension with the temptation for sensational headlines that trivialize a subject like obesity. We’ve seen it before. Yet the current crop of sensational headlines offering a twisted understanding of serious new obesity treatments is especially disappointing. Here’s an example from the supposedly […]
November 7, 2022 — There’s a clue in the strained supply of new obesity and diabetes meds that most everyone is missing. For more than a year now, Novo Nordisk has been unable to produce and distribute an adequate supply of semaglutide in the form of Wegovy for the treatment of obesity. This has knock-on effects. So supply of […]
November 3, 2022 — Mind-blowing. That’s how pediatric obesity medicine expert Claudia Fox described the outcomes with semaglutide for teens with obesity at OW2022 yesterday. As she and a panel of experts in the field discussed this huge advance for teens with obesity, every seat and space to stand in the ballroom was taken. Daniel Weghuber presenting these results […]
November 1, 2022 — Today marks the actual opening of ObesityWeek 2022 in San Diego. So to help you wade through the many hundreds for research studies being presented this week, here is a list of the top ten abstracts at ObesityWeek. Make no mistake. This is a highly subjective list, but it’s ours. Every one of you reading […]
October 31, 2022 — One of the themes you will hear when ObesityWeek gets underway tomorrow in San Diego is the dramatic progress that’s coming into view with new obesity drugs. But the picture quickly becomes murky in the real world because of issues with supply and access to these new and improved obesity meds. The access to care […]
October 15, 2022 — In GQ recently, Will Peischel asked if the world is ready for extremely effective weight-loss drugs. Of course, the simple answer is yes and no. First of all, it’s clear enough that most people don’t really understand these drugs or the condition they treat. Peischel makes that clear right up front when he calls them […]
September 16, 2022 — Twenty years ago in the New England Journal of Medicine, the Diabetes Prevention Program showed that intensive lifestyle coaching for weight control can cut the risk of diabetes for people with prediabetes by 58 percent over a period of three years. At the upcoming EASD meeting, Tim Garvey and colleagues will present an analysis 10-year […]
September 3, 2022 — ICER – the Institute for Clinical and Economic Review – has released its final report on the effectiveness and value of obesity meds and set a public hearing for September 16. Let’s say it right up front. This private nonprofit is trying to do something that is almost impossibly hard. Making objective sense from the […]
August 26, 2022 — Progress keeps coming in the pharmacotherapy for obesity. This week, Novo Nordisk announced that its new combination therapy of semaglutide and cagrilintide hit all its marks in a 32-week phase 2 study of patients with diabetes and excess weight. The combination – Novo is calling it CagriSema – worked better than either semaglutide or cagrilintide […]
